Rapid Seroconversion and Persistent Functional IgG Antibodies in Severe COVID-19 Patients Correlates with an IL-12p70 and IL-33 Signature

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 11

PMID 33568715

Citations 23

Authors

Ariel Munitz

L Edry-Botzer

M Itan

R Tur-Kaspa

D Dicker

D Marcoviciu

M G Goren

M Mor

S Lev

T Gottesman

K Muhsen

D Cohen

M Stein

U Qimron

N T Freund

Y Wine

Motti Gerlic

Affiliations

Soon will be listed here.

Abstract

Despite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. Analysis of the antibody response in mild versus moderate/severe patients, using our new developed quantitative electrochemiluminescent assay for detecting IgM/IgA/IgG antibodies toward SARS-CoV-2 antigens, revealed a rapid onset of IgG/IgA antibodies, specifically in moderate/severe patients. IgM antibodies against the viral receptor binding domain, but not against nucleocapsid protein, were detected at early stages of the disease. Furthermore, we observed a marked reduction in IgM/IgA antibodies over-time. Adapting our assay for ACE2 binding-competition, demonstrated that the presence of potentially neutralizing antibodies is corelated with IgG/IgA. Finally, analysis of the cytokine profile in COVID-19 patients revealed unique correlation of an IL-12p70/IL33 and IgG seroconversion, which correlated with disease severity. In summary, our comprehensive analysis has major implications on the understanding and monitoring of SARS-CoV-2 infections.

Citing Articles

Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data.

Claus J, Ten Doesschate T, Taks E, Debisarun P, Smits G, van Binnendijk R Vaccines (Basel). 2024; 12(6).

PMID: 38932420 PMC: 11209274. DOI: 10.3390/vaccines12060691.

Cytokine, Anti-SARS-CoV-2 Antibody, and Neutralizing Antibody Levels in Conventional Blood Donors Who Have Recovered from COVID-19.

Malicev E, Ziberna K, Jazbec K, Kolenc A, Mali P, Potokar U Transfus Med Hemother. 2024; 51(3):175-184.

PMID: 38867805 PMC: 11166906. DOI: 10.1159/000531942.

Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab.

Dallari S, Martinez Pazos V, Munoz Eusse J, Wellens J, Thompson C, Colombel J Sci Rep. 2024; 14(1):186.

PMID: 38168138 PMC: 10761911. DOI: 10.1038/s41598-023-50035-1.

Immunological Misfiring and Sex Differences/Similarities in Early COVID-19 Studies: Missed Opportunities of Making a Real IMPACT.

Bhargava A, Knapp J Cells. 2023; 12(22).

PMID: 37998327 PMC: 10670326. DOI: 10.3390/cells12222591.

VLP-ELISA for the Detection of IgG Antibodies against Spike, Envelope, and Membrane Antigens of SARS-CoV-2 in Indian Population.

Kumar D, Roy S, Rastogi R, Arora K, Undale A, Gupta R Vaccines (Basel). 2023; 11(4).

PMID: 37112655 PMC: 10145915. DOI: 10.3390/vaccines11040743.

References

Perkmann T, Perkmann-Nagele N, Breyer M, Breyer-Kohansal R, Burghuber O, Hartl S . Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. Clin Chem. 2020; 66(11):1405-1413. PMC: 7454460. DOI: 10.1093/clinchem/hvaa198. View

Sarkar S, Piepenbrink M, Basu M, Thakar J, Keefer M, Hessell A . IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. Vaccine. 2019; 37(17):2322-2330. PMC: 6506229. DOI: 10.1016/j.vaccine.2019.03.044. View

Li Y, Yao L, Li J, Chen L, Song Y, Cai Z . Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020; 92(7):903-908. PMC: 7228231. DOI: 10.1002/jmv.25786. View

Dabitao D, Margolick J, Lopez J, Bream J . Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J Immunol Methods. 2011; 372(1-2):71-7. PMC: 3170504. DOI: 10.1016/j.jim.2011.06.033. View

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B . Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding. Allergy. 2020; 76(3):878-883. PMC: 7984338. DOI: 10.1111/all.14523. View

Pedersen S, Ho Y . SARS-CoV-2: a storm is raging. J Clin Invest. 2020; 130(5):2202-2205. PMC: 7190904. DOI: 10.1172/JCI137647. View

Shlomovitz I, Erlich Z, Speir M, Zargarian S, Baram N, Engler M . Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model. FEBS J. 2018; 286(3):507-522. DOI: 10.1111/febs.14738. View

Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y . A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog. 2020; 16(9):e1008796. PMC: 7482996. DOI: 10.1371/journal.ppat.1008796. View

10.

Stowell S, Guarner J . Role of Serology in the Coronavirus Disease 2019 Pandemic. Clin Infect Dis. 2020; 71(8):1935-1936. PMC: 7197618. DOI: 10.1093/cid/ciaa510. View

11.

Krammer F, Simon V . Serology assays to manage COVID-19. Science. 2020; 368(6495):1060-1061. DOI: 10.1126/science.abc1227. View

12.

Jin J, Bai P, He W, Wu F, Liu X, Han D . Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020; 8:152. PMC: 7201103. DOI: 10.3389/fpubh.2020.00152. View

13.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

14.

Kontis V, Bennett J, Rashid T, Parks R, Pearson-Stuttard J, Guillot M . Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. Nat Med. 2020; 26(12):1919-1928. PMC: 7615092. DOI: 10.1038/s41591-020-1112-0. View

15.

Remuzzi A, Remuzzi G . COVID-19 and Italy: what next?. Lancet. 2020; 395(10231):1225-1228. PMC: 7102589. DOI: 10.1016/S0140-6736(20)30627-9. View

16.

Woo P, Lau S, Wong B, Tsoi H, Fung A, Kao R . Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. J Clin Microbiol. 2005; 43(7):3054-8. PMC: 1169156. DOI: 10.1128/JCM.43.7.3054-3058.2005. View

17.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View

18.

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

19.

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

20.

Bryant J, Azman A, Ferrari M, Arnold B, Boni M, Boum Y . Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol. 2020; 5(47). DOI: 10.1126/sciimmunol.abc6347. View